The 5 most recent market catalysts affecting $VERA, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 15, 2026
Corporate Catalyst
Bullish
Impact 95
Vera Therapeutics shares are trading higher after the company announced that TRUTAKNA met all prespecified endpoints of the final efficacy analysis of the ORIGIN 3 trial in adults with primary IgA nephropathy at risk for disease progression.
This headline represents a major positive catalyst for Vera Therapeutics. Successful clinical trial results, especially meeting all prespecified endpoints in a Phase 3 trial, signi…
Sep 15, 2026
Corporate Catalyst
Bullish
Impact 95
Vera Therapeutics Announces TRUTAKNA Meets All Prespecified Endpoints Of Final Efficacy Analysis Of ORIGIN 3 Trial In Adults With Primary IgA Nephropathy At Risk For Disease Progression
Vera Therapeutics announced highly positive results for its drug TRUTAKNA in the ORIGIN 3 trial for IgA nephropathy, meeting all prespecified efficacy endpoints, including eGFR and…
Sep 8, 2026
Corporate Catalyst
Bullish
Impact 65
JP Morgan Maintains Overweight on Vera Therapeutics, Raises Price Target to $83
JP Morgan analyst Anupam Rama maintained an 'Overweight' rating on Vera Therapeutics and raised the price target from $76 to $83. This action indicates a positive outlook from a ma…
Aug 11, 2026
Corporate Catalyst
Bearish
Impact 55
Wedbush Maintains Neutral on Vera Therapeutics, Lowers Price Target to $34
Wedbush analyst Laura Chico has reduced the price target for Vera Therapeutics (VERA) from $43 to $34, while keeping a Neutral rating. This action indicates a more conservative out…
Aug 10, 2026
Corporate Catalyst
Bearish
Impact 92
Vera Therapeutics Q2 EPS $(1.52) Beats $(1.61) Estimate
Vera Therapeutics announced its Q2 earnings, reporting a loss of $(1.52) per share. While this figure represents a 26.67% increase in losses compared to the prior year, it still ma…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.